AAD 2026Abstract 73493
Bimekizumab leads to sustained flare-free status in moderate to severe hidradenitis suppurativa
3-year data from BE HEARD EXT
Daveluy S, Naik HB, Reguiai Z, Yamaguchi S, Fernandez-Peñas P, Lukowski B, Crater C, Tilt N, Martorell A
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Hidradenitis suppurativa
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.337 · Not in PubMed: details from Crossref